Citation: Boyuan Liu, Zixu Liu, Ping Wang, Yu Zhang, Haibing He, Tian Yin, Jingxin Gou, Xing Tang. Nanomedicine-based targeting delivery systems for peritoneal cavity localized therapy: A promising treatment of ovarian cancer and its peritoneal metastasis[J]. Chinese Chemical Letters, ;2025, 36(6): 110229. doi: 10.1016/j.cclet.2024.110229 shu

Nanomedicine-based targeting delivery systems for peritoneal cavity localized therapy: A promising treatment of ovarian cancer and its peritoneal metastasis

Boyuan Liu ^a ,
Zixu Liu ^a ,
Ping Wang ^b ,
Yu Zhang ^a ,
Haibing He ^a ,
Tian Yin ^c ,
Jingxin Gou ^{a, *,} ,
Xing Tang ^{a, *,}

a.
School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China
b.
School of Pharmacy, Jilin University, Changchun 130021, China
c.
Faculty of Functional Food and Wine, Shenyang Pharmaceutical University, Shenyang 110016, China

jxgou_syphu@163.com

tanglab@126.com

Received Date: 15 May 2024
Revised Date: 2 July 2024
Accepted Date: 8 July 2024
Available Online: 8 July 2024

Figures(3)

As one of the most common gynecological malignancies, peritoneal metastasis is a common feature and cause of high mortality in ovarian cancer (OC). Currently, the standard treatment for OC and its peritoneal metastasis is maximal cytoreductive surgery (CRS) combined with platinum-based chemotherapy. Compared with intravenous chemotherapy, traditional intraperitoneal (IP) chemotherapy exhibits obvious pharmacokinetic (PK) advantages and systemic safety and has shown significant survival benefits in several clinical studies of OC patients. However, there remain several challenges in traditional IP chemotherapy, such as insufficient drug retention, a lack of tumor targeting, inadequate drug penetration, gastrointestinal toxicity, and limited inhibition of tumor metastasis and chemoresistance. Nanomedicine-based IP targeting delivery systems, through specific drug carrier design with tumor cells and tumor environment (TME) targeting, make it possible to overcome these challenges and maximize local therapy efficacy while reducing side effects. In this review article, the rationale and challenges of nanomedicine-based IP chemotherapies, as well as their in vivo fate after IP administration, which are crucial for their rational design and clinical translation, are firstly discussed. Then, current strategies for nanomedicine-based targeting delivery systems and the relevant clinical trials in IP chemotherapy are summarized. Finally, the future directions of the nanomedicine-based IP targeting delivery system for OC and its peritoneal metastasis are proposed, expecting to improve the clinical development of IP chemotherapy.
- Ovarian cancer,
- Peritoneal metastasis,
- Intraperitoneal chemotherapy,
- Nanomedicine-based intraperitoneal targeting delivery system,
- Tumor microenvironment,
- In vivo fate
1. [1]
  S. Lheureux, M. Braunstein, A.M. Oza, CA. Cancer J. Clin. 69 (2019) 280–304. doi: 10.3322/caac.21559
2. [2]
  D. Holmes, Nature 527 (2015) S217. doi: 10.1038/527S217a
3. [3]
  A.J. Cortez, P. Tudrej, K.A. Kujawa, K.M. Lisowska, Cancer Chemother. Pharmacol. 81 (2018) 17–38. doi: 10.1007/s00280-017-3501-8
4. [4]
  S. Breusa, S. Zilio, G. Catania, et al., Front. Oncol. 13 (2023) 1125868. doi: 10.3389/fonc.2023.1125868
5. [5]
  L.C. Peres, K.L. Cushing-Haugen, M. Köbel, et al., J. Natl. Cancer Inst. 111 (2019) 60–68. doi: 10.1093/jnci/djy071
6. [6]
  E. Schoutrop, L. Moyano-Galceran, S. Lheureux, et al., Semin. Cancer Biol. 86 (2022) 207–223. doi: 10.1016/j.semcancer.2022.03.027
7. [7]
  S. Mei, X. Chen, K. Wang, Y. Chen, Cancer Cell Int. 23 (2023) 11. doi: 10.1186/s12935-023-02854-5
8. [8]
  M.A. Lisio, L. Fu, A. Goyeneche, Z.H. Gao, C. Telleria, Int. J. Mol. Sci. 20 (2019) 952. doi: 10.3390/ijms20040952
9. [9]
  J. Krugmann, C. Schwarz, B. Melcher, et al., Arch. Gynecol. Obstet. 299 (2019) 515–523. doi: 10.1007/s00404-018-4952-9
10. [10]
  D.S. Tan, R. Agarwal, S.B. Kaye, Lancet Oncol. 7 (2006) 925–934. doi: 10.1016/S1470-2045(06)70939-1
11. [11]
  T.A. Yap, C.P. Carden, S.B. Kaye, Nat. Rev. Cancer 9 (2009) 167–181. doi: 10.1038/nrc2583
12. [12]
  G.C. Jayson, E.C. Kohn, H.C. Kitchener, J.A. Ledermann, Lancet 384 (2014) 1376–1388. doi: 10.1016/S0140-6736(13)62146-7
13. [13]
  F. Delie, E. Allemann, M. Cohen, J. Drug Deliv. Sci. Technol. 22 (2012) 421–426. doi: 10.1016/S1773-2247(12)50068-7
14. [14]
  Z. Lu, J. Wang, M.G. Wientjes, J.L. Au, Future Oncol. 6 (2010) 1625–1641. doi: 10.2217/fon.10.100
15. [15]
  E. Gitsch, P. Sevelda, S. Schmidl, H. Salzer, Eur. J. Gynaecol. Oncol. 11 (1990) 19–22.
16. [16]
  F.O. Recio, M.S. Piver, R.E. Hempling, D.L. Driscoll, Gynecol. Oncol. 68 (1998) 267–273. doi: 10.1006/gyno.1998.4940
17. [17]
  M.S. Piver, F.O. Recio, T.R. Baker, D. Driscoll, Cancer 73 (1994) 1693–1698. doi: 10.1002/1097-0142(19940315)73:6<1693::AID-CNCR2820730623>3.0.CO;2-0
18. [18]
  R.R. Barakat, P. Sabbatini, D. Bhaskaran, et al., J. Clin. Oncol. 20 (2002) 694–698. doi: 10.1200/JCO.2002.20.3.694
19. [19]
  E. Topuz, P. Saip, A. Aydmer, et al., Eur. J. Gynaecol. Oncol. 19 (1998) 265–270.
20. [20]
  D.S. Alberts, P.Y. Liu, E.V. Hannigan, et al., N. Engl. J. Med. 335 (1996) 1950–1955. doi: 10.1056/NEJM199612263352603
21. [21]
  M. Markman, B. Reichman, T. Hakes, et al., J. Cancer Res. Clin. Oncol. 118 (1992) 235–237. doi: 10.1007/BF01410140
22. [22]
  Z. Luo, Q. Wang, W. Lau, et al., Cancer Lett. 377 (2016) 174–182. doi: 10.1016/j.canlet.2016.04.038
23. [23]
  M. Castells, B. Thibault, J.P. Delord, B. Couderc, Int. J. Mol. Sci. 13 (2012) 9545–9571. doi: 10.3390/ijms13089545
24. [24]
  X. Huang, M. Qiu, T. Wang, et al., J. Nanobiotechnol. 20 (2022) 93. doi: 10.1186/s12951-022-01300-4
25. [25]
  A.H. Colby, S.M. Berry, A.M. Moran, et al., ACS Nano 11 (2017) 1466–1477. doi: 10.1021/acsnano.6b06777
26. [26]
  B.T. Surikutchi, R. Obenza-Otero, E. Russo, et al., Int. J. Pharm. 622 (2022) 121828. doi: 10.1016/j.ijpharm.2022.121828
27. [27]
  A. Oseledchyk, C. Andreou, M.A. Wall, M.F. Kircher, ACS Nano 11 (2017) 1488–1497. doi: 10.1021/acsnano.6b06796
28. [28]
  K. Yamaguchi, O. Hiraike, H. Iwaki, et al., Mol. Pharmaceutics 18 (2021) 4090–4098. doi: 10.1021/acs.molpharmaceut.1c00514
29. [29]
  K. Qian, H. Qian, J. Cai, et al., Patho. Res. Pract. 215 (2019) 755–760. doi: 10.1016/j.prp.2019.01.005
30. [30]
  J. Luo, Z. Wu, Y. Lu, et al., Int. J. Biol. Macromol. 152 (2020) 718–726. doi: 10.1016/j.ijbiomac.2020.02.326
31. [31]
  J. Kim, M.K. Shim, Y.J. Cho, et al., Biomaterials 279 (2021) 121189. doi: 10.1016/j.biomaterials.2021.121189
32. [32]
  M. Qiu, J. Chen, X. Huang, et al., ACS Appl. Mater. Interfaces 14 (2022) 21954–21965. doi: 10.1021/acsami.2c02552
33. [33]
  V. Mulens-Arias, A. Nicolás-Boluda, A. Pinto, et al., ACS Nano 15 (2021) 3330–3348. doi: 10.1021/acsnano.0c10276
34. [34]
  R. Liu, A.H. Colby, D. Gilmore, et al., Biomaterials 102 (2016) 175–186. doi: 10.1016/j.biomaterials.2016.06.031
35. [35]
  S. Xu, H. Fan, L. Yin, et al., Eur. J. Pharm. Biopharm. 104 (2016) 251–259. doi: 10.1007/s11071-015-2426-1
36. [36]
  D. Hargrove, B. Liang, R. Kashfi-Sadabad, et al., J. Control. Release 328 (2020) 846–858. doi: 10.1016/j.jconrel.2020.11.003
37. [37]
  D.H. Shin, G.S. Kwon, J. Control. Release 268 (2017) 176–183. doi: 10.1016/j.jconrel.2017.10.022
38. [38]
  M. Shariati, G. Lollo, K. Matha, et al., ACS Appl. Mater. Interfaces 12 (2020) 29024–29036.
39. [39]
  D. Yang, Y. Fan, C. Emiliano, et al., Proc. Natl. Acad. Sci. U. S. A. 113 (2016) 11453–11458. doi: 10.1073/pnas.1523141113
40. [40]
  G.R. Dakwar, M. Shariati, W. Willaert, et al., Adv. Drug Deliv. Rev. 108 (2017) 13–24. doi: 10.1016/j.addr.2016.07.001
41. [41]
  R. Ando-Matsuoka, H. Ando, A.S. Abu Lila, et al., J. Control. Release 341 (2022) 524–532. doi: 10.1016/j.jconrel.2021.12.004
42. [42]
  N. Mirahmadi, M.H. Babaei, A.M. Vail, S. Dadashzadeh, Int. J. Pharm. 383 (2010) 7–13. doi: 10.1016/j.ijpharm.2009.08.034
43. [43]
  X.F. Li, S. Carlin, M. Urano, et al., Cancer Res. 67 (2007) 7646–7653. doi: 10.1158/0008-5472.CAN-06-4353
44. [44]
  L. Kuroki, S.R. Guntupalli, BMJ. 371 (2020) m3773. doi: 10.1136/bmj.m3773
45. [45]
  W. Ceelen, H. Braet, G. Van Ramshorst, et al., Expert Opin. Drug Deliv. 17 (2020) 511–522. doi: 10.1080/17425247.2020.1736551
46. [46]
  P.A. Netti, D.A. Berk, M.A. Swartz, A.J. Grodzinsky, R.K. Jain, Cancer Res. 60 (2000) 2497–2503.
47. [47]
  R.K. Jain, Cancer Res. 47 (1987) 3039–3051.
48. [48]
  E.W. Young, Integr. Biol. 5 (2013) 1096–1109. doi: 10.1039/c3ib40076j
49. [49]
  Y. Sadzuka, S. Hirota, T. Sonobe, Toxicol. Lett. 116 (2000) 51–59. doi: 10.1016/S0378-4274(00)00201-0
50. [50]
  S. Dadashzadeh, N. Mirahmadi, M.H. Babaei, A.M. Vali, J. Control. Release. 148 (2010) 177–186. doi: 10.1016/j.jconrel.2010.08.026
51. [51]
  T. Haber, Y.R. Cornejo, S. Aramburo, et al., Proc. Natl. Acad. Sci. U. S. A. 117 (2020) 19737–19745. doi: 10.1073/pnas.1917424117
52. [52]
  Y. Kai, G. Hua, S. Xiaoze, et al., Biomaterials 34 (2013) 2787–2795. doi: 10.1016/j.biomaterials.2013.01.001
53. [53]
  D.S. Kohane, J.Y. Tse, Y. Yeo, et al., J. Biomed. Mater. Res. A 77 (2006) 351–361. doi: 10.1002/jbm.a.30654
54. [54]
  K. Hirano, C.A. Hunt, J. Pharm. Sci. 74 (1985) 915–921. doi: 10.1002/jps.2600740902
55. [55]
  P. Maincent, P. Thouvenot, C. Amicabile, et al., Pharm. Res. 9 (1992) 1534–1539. doi: 10.1023/A:1015895804597
56. [56]
  G. Bajaj, Y. Yeo, Pharm. Res. 27 (2010) 735–738. doi: 10.1007/s11095-009-0031-z
57. [57]
  K. De Clercq, C. Schelfhout, M. Bracke, et al., Biomaterials 96 (2016) 33–46. doi: 10.1016/j.biomaterials.2016.04.012
58. [58]
  B.S. Zolnik, Á. González-Fernández, N. Sadrieh, M.A. Dobrovolskaia, Endocrinology 151 (2010) 458–465. doi: 10.1210/en.2009-1082
59. [59]
  G. Dakwar, E. Zagato, J. Delanghe, et al., Acta Biomater. 10 (2014) 2965–2975. doi: 10.1016/j.actbio.2014.03.012
60. [60]
  Q. Jianping, Z. Jie, L. Yi, et al., Drug Discov. Today 22 (2017) 166–172. doi: 10.1016/j.drudis.2016.09.024
61. [61]
  K. Saha, M. Rahimi, M. Yazdani, et al., ACS Nano 10 (2016) 4421–4430. doi: 10.1021/acsnano.6b00053
62. [62]
  C. Zhi-Ting, G. Li-Qin, J. Wei, et al., ACS Nano 14 (2020) 3563–3575. doi: 10.1021/acsnano.9b10015
63. [63]
  G. Caracciolo, L. Callipo, S.C. De Sanctis, et al., Biophys. Acta 1798 (2010) 536–543. doi: 10.1016/j.bbamem.2009.11.007
64. [64]
  G. Caracciolo, F. Cardarelli, D. Pozzi, et al., ACS Appl. Mater. Interfaces 5 (2013) 13171–13179. doi: 10.1021/am404171h
65. [65]
  S. Schöttler, G. Becker, S. Winzen, et al., Nat. Nanotechnol. 11 (2016) 372–377. doi: 10.1038/nnano.2015.330
66. [66]
  M. Tonigold, J. Simon, D. Estupiñán, et al., Nat. Nanotechnol. 13 (2018) 862–869. doi: 10.1038/s41565-018-0171-6
67. [67]
  V. Mirshafiee, M. Mahmoudi, K. Lou, J. Cheng, M.L. Kraft, Chem. Commun. 49 (2013) 2557–2559. doi: 10.1039/c3cc37307j
68. [68]
  A. Salvati, A.S. Pitek, M.P. Monopoli, et al., Nat. Nanotechnol. 8 (2013) 137–143. doi: 10.1038/nnano.2012.237
69. [69]
  R. Dedrick, Semin. Oncol. 12 (1985) 1–6.
70. [70]
  S. Zimm, S.M. Cleary, W.E. Lucas, et al., Cancer Res. 47 (1987) 1712–1716.
71. [71]
  M. Markman, Intraperitoneal chemotherapy, in: A. Altchek, L. Deligdisch, N.G. Kase (Eds.), Diagnosis and Management of Ovarian Disorders, 2nd Edition, Academic Press, San Diego, 2003, pp. 505–513.
72. [72]
  V.P. Chauhan, R.M. Lanning, B. Diop-Frimpong, et al., Biophys. J. 97 (2009) 330–336. doi: 10.1016/j.bpj.2009.03.064
73. [73]
  J. Leal, H.D. Smyth, D. Ghosh, Int. J. Pharm. 532 (2017) 555–572. doi: 10.1016/j.ijpharm.2017.09.018
74. [74]
  M. Zhang, Z. Chen, Y. Wang, H. Zhao, Y. Du, Cancers 14 (2022) 2637. doi: 10.3390/cancers14112637
75. [75]
  A. Garcia-Gomez, J. Rodríguez-Ubreva, E. Ballestar, Clin. Immunol. 196 (2018) 64–71. doi: 10.1016/j.clim.2018.02.013
76. [76]
  F. Elferink, W. Van Der Vijgh, I. Klein, et al., Cancer Chemother. Pharmacol. 21 (1988) 57–60. doi: 10.1007/BF00262740
77. [77]
  J.D. Nagel, F.J. Varossieau, R. Dubbelman, W.W. ten Bokkel Huinink, J.G. McVie, Cancer Chemother. Pharmacol. 29 (1992) 480–484. doi: 10.1007/BF00684852
78. [78]
  M. Markman, E. Rowinsky, T. Hakes, et al., J. Clin. Oncol. 10 (1992) 1485–1491. doi: 10.1200/JCO.1992.10.9.1485
79. [79]
  D.S. Alberts, E.A. Surwit, Y.M. Peng, et al., Cancer Res. 48 (1988) 5874–5877.
80. [80]
  R. Demicheli, G. Bonciarelli, A. Jirillo, et al., Tumori. 71 (1985) 63–68. doi: 10.1177/030089168507100112
81. [81]
  S.B. Howell, C.E. Pfeifle, R.A. Olshen, Ann. Intern. Med. 101 (1984) 14–18. doi: 10.7326/0003-4819-101-1-14
82. [82]
  B.J. Monk, E.A. Surwit, D.S. Alberts, V. Graham, Semin. Oncol. 15 (1988) 27–31.
83. [83]
  R.J.Morgan Jr, J.H. Doroshow, T. Synold, et al., Clin. Cancer Res. 9 (2003) 5896–5901.
84. [84]
  J.L. Speyer, J.M. Collins, R.L. Dedrick, et al., Cancer Res. 40 (1980) 567–572.
85. [85]
  D.M. Elias, L. Sideris, Surg. Oncol. Clin. N. Am. 12 (2003) 755–769. doi: 10.1016/S1055-3207(03)00051-6
86. [86]
  L.B. Wenzel, H.Q. Huang, D.K. Armstrong, J.L. Walker, D. Cella, J. Clin. Oncol. 25 (2007) 437–443. doi: 10.1200/JCO.2006.07.3494
87. [87]
  J.L. Walker, D.K. Armstrong, H.Q. Huang, et al., Gynecol. Oncol. 100 (2006) 27–32. doi: 10.1016/j.ygyno.2005.11.013
88. [88]
  Y. Minareci, O.A. Tosun, H. Sozen, S. Topuz, M.Y. Salihoglu, Medeni. Med. J. 35 (2020) 202–211.
89. [89]
  A. Ghoneum, S. Almousa, B. Warren, et al., Semin. Cancer Biol. 77 (2021) 83–98. doi: 10.1016/j.semcancer.2020.12.024
90. [90]
  L. Huang, C. Perrault, J. Coelho-Martins, et al., J. Hematol. Oncol. 6 (2013) 49. doi: 10.1186/1756-8722-6-49
91. [91]
  K. Hida, N. Maishi, Y. Sakurai, Y. Hida, H. Harashima, Adv. Drug Deliv. Rev. 99 (2016) 140–147. doi: 10.1016/j.addr.2015.11.008
92. [92]
  D.A. Annan, H. Kikuchi, N. Maishi, Y. Hida, K. Hida, Int. J. Mol. Sci. 21 (2020) 3238. doi: 10.3390/ijms21093238
93. [93]
  C.A. Penn, K. Yang, H. Zong, et al., Mol. Cancer Ther. 17 (2018) 96–106.
94. [94]
  J. Wang, Y. Li, G. Nie, Nat. Rev. Mater. 6 (2021) 766–783. doi: 10.1038/s41578-021-00315-x
95. [95]
  K. Stratakis, T. Arkoumanis, A. Liakea, et al., Chirurgia (Bucur) 117 (2022) 585–593. doi: 10.21614/chirurgia.2737
96. [96]
  G.U. Ruiz-Esparza, X. Wang, X. Zhang, et al., Nanomicro Lett. 13 (2021) 212.
97. [97]
  E.M. Ahmed, J. Adv. Res. 6 (2015) 105–121. doi: 10.1016/j.jare.2013.07.006
98. [98]
  Y. Huang, J. Zheng, G. Zeng, et al., Mater. Today Bio. 24 (2024) 100931. doi: 10.1016/j.mtbio.2023.100931
99. [99]
  M. Norouzi, B. Nazari, D.W. Miller, Drug Discov. Today 21 (2016) 1835–1849. doi: 10.1016/j.drudis.2016.07.006
100. [100]
  Z. Li, J. Guan, Expert Opin. Drug Deliv. 8 (2011) 991–1007. doi: 10.1517/17425247.2011.581656
101. [101]
  W. Shen, X. Chen, J. Luan, et al., ACS Appl. Mater. Interfaces 9 (2017) 40031–40046. doi: 10.1021/acsami.7b11998
102. [102]
  M. Longmire, P.L. Choyke, H. Kobayashi, Nanomedicine 3 (2008) 703–717. doi: 10.2217/17435889.3.5.703
103. [103]
  M.F. Flessner, J.D. Fenstermacher, R.G. Blasberg, R.L. Dedrick, Am. J. Physiol. Heart Circ. Physiol. 248 (1985) H26–H32. doi: 10.1152/ajpheart.1985.248.1.H26
104. [104]
  A. Supersaxo, W.R. Hein, H. Steffen, Pharm. Res. 8 (1991) 1286–1291. doi: 10.1023/A:1015807913934
105. [105]
  G. Lee, S. Han, I. Inocencio, et al., Mol. Pharm. 16 (2019) 4987–4999. doi: 10.1021/acs.molpharmaceut.9b00855
106. [106]
  Y. Aramaki, K. Akiyama, T. Hara, S. Tsuchiya, Eur. J. Pharm. Sci. 3 (1995) 63–70. doi: 10.1016/0928-0987(94)00075-B
107. [107]
  M.J. Ernsting, M. Murakami, A. Roy, S.D. Li, J. Control. Release 172 (2013) 782–794. doi: 10.1016/j.jconrel.2013.09.013
108. [108]
  T. Stylianopoulos, M.Z. Poh, N. Insin, et al., Biophys. J. 99 (2010) 1342–1349. doi: 10.1016/j.bpj.2010.06.016
109. [109]
  O. Lieleg, R.M. Baumgärtel, A.R. Bausch, Biophys. J. 97 (2009) 1569–1577. doi: 10.1016/j.bpj.2009.07.009
110. [110]
  T. Nomura, N. Koreeda, F. Yamashita, Y. Takakura, M. Hashida, Pharm. Res. 15 (1998) 128–132. doi: 10.1023/A:1011921324952
111. [111]
  H.X. Wang, Z.Q. Zuo, J.Z. Du, et al., Nano Today 11 (2016) 133–144. doi: 10.1016/j.nantod.2016.04.008
112. [112]
  H. Lee, H. Fonge, B. Hoang, R.M. Reilly, C. Allen, Mol. Pharm. 7 (2010) 1195–1208. doi: 10.1021/mp100038h
113. [113]
  M. Murakami, M. Ernsting, E. Undzys, et al., Cancer Res. 73 (2013) 4862–4871.
114. [114]
  J.H. Zheng, C.T. Chen, J.L. Au, M.G. Wientjes, AAPS PharmSci. 3 (2001) E15. doi: 10.1208/ps030318
115. [115]
  H.J. Kuh, S.H. Jang, M.G. Wientjes, J.R. Weaver, J.L. Au, J. Pharmacol. Exp. Ther. 290 (1999) 871–880. doi: 10.1016/S0022-3565(24)34976-6
116. [116]
  S.H. Jang, M.G. Wientjes, J.L. Au, J. Pharmacol. Exp. Ther. 296 (2001) 1035–1042. doi: 10.1016/S0022-3565(24)38848-2
117. [117]
  C.T. Chen, J.L. Au, M.G. Wientjes, Clin. Cancer Res. 4 (1998) 277–282.
118. [118]
  D. Lu, M.G. Wientjes, Z. Lu, J.L. Au, J. Pharmacol. Exp. Ther. 322 (2007) 80–88. doi: 10.1124/jpet.107.121632
119. [119]
  S.H. Jang, M.G. Wientjes, J.L. Au, Invest. New Drugs 19 (2001) 113–123. doi: 10.1023/A:1010662413174
120. [120]
  G. Griffon-Etienne, Y. Boucher, C. Brekken, H.D. Suit, R.K. Jain, Cancer Res. 59 (1999) 3776–3782.
121. [121]
  K. Pietras, Semin. Oncol. 31 (2004) 18–23.
122. [122]
  K. Pietras, A. Ostman, M. Sjöquist, et al., Cancer Res. 61 (2001) 2929–2934.
123. [123]
  R. Cairns, I. Papandreou, N. Denko, Mol. Cancer Res. 4 (2006) 61–70. doi: 10.1158/1541-7786.MCR-06-0002
124. [124]
  Y. Yeo, T. Ito, E. Bellas, et al., Ann. Surg. 245 (2007) 819–824. doi: 10.1097/01.sla.0000251519.49405.55
125. [125]
  F. Mohamed, O.A. Stuart, P.H. Sugarbaker, J. Surg. Res. 113 (2003) 114–120. doi: 10.1016/S0022-4804(03)00162-8
126. [126]
  L. Yu, Z. Luo, T. Chen, et al., Int. J. Mol. Sci. 23 (2022) 2370. doi: 10.3390/ijms23042370
127. [127]
  S.K. Nethi, S. Das, C.R. Patra, S.J.B.S. Mukherjee, Biomater. Sci. 7 (2019) 2652–2674. doi: 10.1039/c9bm00423h
128. [128]
  S. Xiao, Y. Wang, W. Ma, et al., Drug Deliv. 29 (2022) 2713–2722. doi: 10.1080/10717544.2022.2111480
129. [129]
  Q. He, J. Chen, J. Yan, et al., Asian J. Pharm. Sci. 15 (2020) 416–448.
130. [130]
  T.M. Allen, Nat. Rev. Cancer 2 (2002) 750–763. doi: 10.1038/nrc903
131. [131]
  L. Zhao, W. Yuan, J. Li, et al., Adv. Funct. Mater. 28 (2018) 1806162. doi: 10.1002/adfm.201806162
132. [132]
  R.K. Jain, Adv. Drug Delivery Rev. 64 (2012) 353–365. doi: 10.1016/j.addr.2012.09.011
133. [133]
  W. Chen, K. Shi, Y. Yu, et al., Chin. Chem. Lett. 35 (2023) 109159. doi: 10.1016/j.cclet.2023.109159
134. [134]
  R.H. Fang, W. Gao, L. Zhang, Nat. Rev. Clin. Oncol. 20 (2023) 33–48. doi: 10.1038/s41571-022-00699-x
135. [135]
  C. Guido, G. Maiorano, B. Cortese, S. D’Amone, I.E. Palamà, Bioengineering 7 (2020) 111. doi: 10.3390/bioengineering7030111
136. [136]
  C. Andreou, A. Oseledchyk, F. Nicolson, et al., J. Visualized Exp., 145 (2019) e58389.
137. [137]
  H.D. Han, L.S. Mangala, J.W. Lee, et al., Clin. Cancer Res. 16 (2010) 3910–3922. doi: 10.1158/1078-0432.CCR-10-0005
138. [138]
  U.K. Nässander, P.A. Steerenberg, H. Poppe, et al., Cancer Res. 52 (1992) 646–653.
139. [139]
  M. Satpathy, L. Wang, R. Zielinski, et al., Small 10 (2014) 544–555. doi: 10.1002/smll.201301593
140. [140]
  V. Shah, O. Taratula, O.B. Garbuzenko, et al., Clin. Cancer Res. 19 (2013) 6193–6204. doi: 10.1158/1078-0432.CCR-13-1536
141. [141]
  Y. Yang, X. Zhao, X. Li, et al., Oncol. Lett. 13 (2017) 99–104. doi: 10.3892/ol.2016.5413
142. [142]
  K. Gong, J. Liao, J. Lin, et al., Chin. Chem. Lett. 35 (2024) 108888. doi: 10.1016/j.cclet.2023.108888
143. [143]
  P. Zheng, Y. Liu, J. Chen, et al., Chin. Chem. Lett. 31 (2020) 1178–1182. doi: 10.1016/j.cclet.2019.12.001
144. [144]
  D. Kim, Z.G. Gao, E.S. Lee, Y.H. Bae, Mol. Pharm. 6 (2009) 1353–1362. doi: 10.1021/mp900021q
145. [145]
  Y. Zheng, Z. Cai, X. Song, et al., Int. J. Pharm. 382 (2009) 262–269. doi: 10.1016/j.ijpharm.2009.08.009
146. [146]
  M.H. Vingerhoeds, P.A. Steerenberg, J.J. Hendriks, et al., Br. J. Cancer 74 (1996) 1023–1029. doi: 10.1038/bjc.1996.484
147. [147]
  A. Cirstoiu-Hapca, F. Buchegger, N. Lange, et al., J. Control. Release 144 (2010) 324–331. doi: 10.1016/j.jconrel.2010.02.026
148. [148]
  W. Chen, R. Bardhan, M. Bartels, et al., Mol. Cancer Ther. 9 (2010) 1028–1038. doi: 10.1158/1535-7163.MCT-09-0829
149. [149]
  L. Ceppi, N.M. Bardhan, Y. Na, et al., ACS Nano 13 (2019) 5356–5365. doi: 10.1021/acsnano.8b09829
150. [150]
  C. Schumann, S. Chan, J.A. Millar, et al., Nanomedicine 14 (2018) 1395–1405. doi: 10.1016/j.nano.2018.03.005
151. [151]
  L.B. Mensah, S.W. Morton, J. Li, H. Xiao, et al., Bioeng. Transl. Med. 4 (2019) e10131. doi: 10.1002/btm2.10131
152. [152]
  A.C. Khayrani, H. Mahmud, A.K.K. Oo, et al., Int. J. Mol. Sci. 20 (2019) 1042. doi: 10.3390/ijms20051042
153. [153]
  F. Delie, P. Ribaux, P. Petignat, M.J.B. Cohen, Biochimie 94 (2012) 2391–2397. doi: 10.1016/j.biochi.2012.06.010
154. [154]
  I.R. Corbin, K.K. Ng, L. Ding, A. Jurisicova, G. Zheng, Nanomedicine 8 (2013) 875–890. doi: 10.2217/nnm.12.137
155. [155]
  A. Li, Y. Zhao, Y. Li, et al., Drug Deliv. 28 (2021) 1237–1255. doi: 10.1080/10717544.2021.1938757
156. [156]
  B. Bahmani, H. Gong, B.T. Luk, et al., Nat. Commun. 12 (2021) 1999. doi: 10.1038/s41467-021-22311-z
157. [157]
  Y. Li, R. Yuan, Y. Luo, et al., Adv. Mater. 35 (2023) 2300216. doi: 10.1002/adma.202300216
158. [158]
  H. Qian, K. Qian, J. Cai, et al., ACS Biomater. Sci. Eng. 5 (2019) 1100–1112. doi: 10.1021/acsbiomaterials.8b01557
159. [159]
  J. Wang, H. Pan, J. Li, et al., Chin. Chem. Lett. 34 (2023) 107828. doi: 10.1016/j.cclet.2022.107828
160. [160]
  G. Yang, Y. Liu, J. Chen, J. Ding, X. Chen, Acc. Mater. Res. 3 (2022) 1232–1247. doi: 10.1021/accountsmr.2c00147
161. [161]
  G. Li, W. Xu, Y. Shi, M. Chen, D. Peng, J. Biomed. Nanotechnol. 18 (2022) 718–728. doi: 10.1166/jbn.2022.3303
162. [162]
  H. Fu, P. Liang, Q. Chen, et al., Chin. Chem. Lett. 35 (2024) 109241. doi: 10.1016/j.cclet.2023.109241
163. [163]
  J. Wang, X. Pan, J. Zhang, et al., Chin. Chem. Lett. 35 (2024) 109187. doi: 10.1016/j.cclet.2023.109187
164. [164]
  L. Simón-Gracia, H. Hunt, P. Scodeller, J. Gaitzsch, et al., Biomaterials 104 (2016) 247–257. doi: 10.1016/j.biomaterials.2016.07.023
165. [165]
  Y. Yan, Y. Dong, S. Yue, et al., ACS Appl. Mater. Interfaces 11 (2019) 46548–46557. doi: 10.1021/acsami.9b17223
166. [166]
  J. Yang, T. Su, H. Zou, et al., Angew. Chem. 134 (2022) e202211136. doi: 10.1002/ange.202211136
167. [167]
  Y. Feng, Z. Liao, H. Zhang, et al., Chem. Eng. J. 452 (2023) 139506. doi: 10.1016/j.cej.2022.139506
168. [168]
  Y. Jiang, C. Wang, S. Zhou, Biochim. Biophys. Acta Rev. Cancer 1873 (2020) 188361. doi: 10.1016/j.bbcan.2020.188361
169. [169]
  M. Cummings, C. Freer, N. Orsi, Semin. Cancer Biol. 77 (2021) 3–28. doi: 10.1016/j.semcancer.2021.02.007
170. [170]
  P. Lu, V.M. Weaver, Z. Werb, J. Cell Biol. 196 (2012) 395–406. doi: 10.1083/jcb.201102147
171. [171]
  T.Y. Yu, G. Zhang, X.X. Chai, et al., Life Sci. 332 (2023) 122084. doi: 10.1016/j.lfs.2023.122084
172. [172]
  K. Dzobo, C. Dandara, Biomimetics 8 (2023) 146. doi: 10.3390/biomimetics8020146
173. [173]
  Y. Brown, S. Hua, P.S. Tanwar, Matrix. Biol. 118 (2023) 16–46. doi: 10.1016/j.matbio.2023.02.004
174. [174]
  L. Pascual-Antón, P. Sandoval, G.T. González-Mateo, et al., J. Pathol. 261 (2023) 238–251. doi: 10.1002/path.6170
175. [175]
  J.M. Hansen, R.L. Coleman, A.K. Sood, Eur. J. Cancer 56 (2016) 131–143. doi: 10.1016/j.ejca.2015.12.016
176. [176]
  H. Peng, X. He, Q. Wang, Front. Immunol. 13 (2022) 1035997. doi: 10.3389/fimmu.2022.1035997
177. [177]
  J. Guo, H. Zeng, Y. Chen, Mol. Pharm. 17 (2020) 1028–1048. doi: 10.1021/acs.molpharmaceut.0c00014
178. [178]
  J. Schmitt, D. Matei, Cancer Treat. Rev. 38 (2012) 272–283. doi: 10.1016/j.ctrv.2011.06.004
179. [179]
  F. Danhier, O. Feron, V. Préat, J. Control. Release 148 (2010) 135–146. doi: 10.1016/j.jconrel.2010.08.027
180. [180]
  D. Ribatti, T. Annese, S. Ruggieri, R. Tamma, E. Crivellato, Transl. Oncol. 12 (2019) 981–986. doi: 10.1016/j.tranon.2019.04.022
181. [181]
  K. Yoncheva, G. Momekov, Expert Opin. Drug Deliv. 8 (2011) 1041–1056. doi: 10.1517/17425247.2011.585155
182. [182]
  R. Giordo, Z. Wehbe, P. Paliogiannis, et al., Semin. Cancer Biol. 86 (2022) 784–804. doi: 10.1016/j.semcancer.2022.03.001
183. [183]
  G. Hu, M. Guo, J. Xu, et al., Front. Immunol. 10 (2019) 475392.
184. [184]
  M. Ovais, M. Guo, C. Chen, Adv. Mater. 31 (2019) 1808303. doi: 10.1002/adma.201808303
185. [185]
  P.S. Kirk, T. Koreckij, H.M. Nguyen, et al., Int. J. Mol. Sci. 14 (2013) 10483–10496. doi: 10.3390/ijms140510483
186. [186]
  D.E. Sanford, B.A. Belt, R.Z. Panni, et al., Clin. Cancer Res. 19 (2013) 3404–3415. doi: 10.1158/1078-0432.CCR-13-0525
187. [187]
  F.J. Van Dalen, M.H. Van Stevendaal, F.L. Fennemann, M. Verdoes, O.J.M. Ilina, Molecules 24 (2018) 9. doi: 10.3390/molecules24010009
188. [188]
  E.B. Glass, A.A. Hoover, K.K. Bullock, et al., BMC Cancer 22 (2022) 497. doi: 10.1186/s12885-022-09612-2
189. [189]
  E.L. Yang, Z.J. Sun, Adv. Healthc. Mater. 13 (2024) e2303294. doi: 10.1002/adhm.202303294
190. [190]
  S.B. Yong, J.Y. Chung, Y. Song, et al., Biomaterials 219 (2019) 119401. doi: 10.1016/j.biomaterials.2019.119401
191. [191]
  F. Rodríguez, P. Caruana, N.De la Fuente, et al., Biomolecules 12 (2022) 784. doi: 10.3390/biom12060784
1. [1]
  Huijiao Fu , Peiqin Liang , Qianwen Chen , Yan Wang , Guang Li , Xuzi Cai , Shengtao Wang , Kun Chen , Shengying Shi , Zhiqiang Yu , Xuefeng Wang . COX-2 blocking therapy in cisplatin chemosensitization of ovarian cancer: An allicin-based nanomedicine approach. Chinese Chemical Letters, 2024, 35(8): 109241-. doi: 10.1016/j.cclet.2023.109241
2. [2]
  Fengyun Li , Zerong Pei , Shuting Chen , Gen li , Mengyang Liu , Liqin Ding , Jingbo Liu , Feng Qiu . Multifunctional nano-herb based on tumor microenvironment for enhanced tumor therapy of gambogic acid. Chinese Chemical Letters, 2024, 35(5): 108752-. doi: 10.1016/j.cclet.2023.108752
3. [3]
  Li Fu , Ziye Su , Shuyang Wu , Yanfen Cheng , Chuan Hu , Jinming Zhang . Redox-responsive hyaluronic acid-celastrol prodrug micelles with glycyrrhetinic acid co-delivery for tumor combination therapy. Chinese Chemical Letters, 2025, 36(5): 110227-. doi: 10.1016/j.cclet.2024.110227
4. [4]
  Huijie An , Chen Yang , Zhihui Jiang , Junjie Yuan , Zhongming Qiu , Longhao Chen , Xin Chen , Mutu Huang , Linlang Huang , Hongju Lin , Biao Cheng , Hongjiang Liu , Zhiqiang Yu . Luminescence-activated Pt(Ⅳ) prodrug for in situ triggerable cancer therapy. Chinese Chemical Letters, 2024, 35(7): 109134-. doi: 10.1016/j.cclet.2023.109134
5. [5]
  Zhendong Liu , Sainan Liu , Bin Liu , Qi Meng , Meng Yuan , Chunzheng Yang , Yulong Bian , Ping'an Ma , Jun Lin . Fe(Ⅲ)-juglone nanoscale coordination polymers for cascade chemodynamic therapy through synergistic ferroptosis and apoptosis strategy. Chinese Chemical Letters, 2024, 35(11): 109626-. doi: 10.1016/j.cclet.2024.109626
6. [6]
  Yunkang Tong , Haiqiao Huang , Haolan Li , Mingle Li , Wen Sun , Jianjun Du , Jiangli Fan , Lei Wang , Bin Liu , Xiaoqiang Chen , Xiaojun Peng . Cooperative bond scission by HRP/H₂O₂ for targeted prodrug activation. Chinese Chemical Letters, 2024, 35(12): 109663-. doi: 10.1016/j.cclet.2024.109663
7. [7]
  Yanfei Liu , Yaqin Hu , Yifu Tan , Qiwen Chen , Zhenbao Liu . Tumor acidic microenvironment activatable DNA nanostructure for precise cancer cell targeting and inhibition. Chinese Chemical Letters, 2025, 36(1): 110289-. doi: 10.1016/j.cclet.2024.110289
8. [8]
  Honghao Sun , Huimin Zhao , Ronghui Yin , Chenxi Zhou , Ming Wu , Yueyang Deng , Zhanwei Zhou , Minjie Sun . Injectable hydrogel-based tumor vaccine with fibrotic tumor immune microenvironment remodeling to prevent breast cancer postoperative recurrence and metastases. Chinese Chemical Letters, 2025, 36(5): 110067-. doi: 10.1016/j.cclet.2024.110067
9. [9]
  Wenbin Zhou , Yafei Gao , Xinyu Feng , Yanqing Zhang , Cong Yang , Lanxi He , Fenghe Zhang , Xiaoguang Li , Qing Li . Biomimetic nanoplatform integrates FRET-enhanced photodynamic therapy and chemotherapy for cascaded revitalization of the tumor immune microenvironment in OSCC. Chinese Chemical Letters, 2025, 36(1): 109763-. doi: 10.1016/j.cclet.2024.109763
10. [10]
  Yanhua Chen , Xian Ding , Jun Zhou , Zhaoying Wang , Yunhai Bo , Ying Hu , Qingce Zang , Jing Xu , Ruiping Zhang , Jiuming He , Fen Yang , Zeper Abliz . Plasma metabolomics combined with mass spectrometry imaging reveals crosstalk between tumor and plasma in gastric cancer genesis and metastasis. Chinese Chemical Letters, 2025, 36(1): 110351-. doi: 10.1016/j.cclet.2024.110351
11. [11]
  Jiaqi Huang , Renjiang Kong , Yanmei Li , Ni Yan , Yeyang Wu , Ziwen Qiu , Zhenming Lu , Xiaona Rao , Shiying Li , Hong Cheng . Feedback enhanced tumor targeting delivery of albumin-based nanomedicine to amplify photodynamic therapy by regulating AMPK signaling and inhibiting GSTs. Chinese Chemical Letters, 2024, 35(8): 109254-. doi: 10.1016/j.cclet.2023.109254
12. [12]
  Cheng-Zhe Gao , Hao-Ran Jia , Tian-Yu Wang , Xiao-Yu Zhu , Xiaofeng Han , Fu-Gen Wu . A dual drug-loaded tumor vasculature-targeting liposome for tumor vasculature disruption and hypoxia-enhanced chemotherapy. Chinese Chemical Letters, 2025, 36(1): 109840-. doi: 10.1016/j.cclet.2024.109840
13. [13]
  Yi Cao , Xiaojiao Ge , Yuanyuan Wei , Lulu He , Aiguo Wu , Juan Li . Tumor microenvironment-activatable neuropeptide-drug conjugates enhanced tumor penetration and inhibition via multiple delivery pathways and calcium deposition. Chinese Chemical Letters, 2024, 35(4): 108672-. doi: 10.1016/j.cclet.2023.108672
14. [14]
  Chenlu Huang , Xinyu Yang , Qingyu Yu , Linhua Zhang , Dunwan Zhu . Gas-generating polymersomes-based amplified photoimmunotherapy for abscopal effect and tumor metastasis inhibition. Chinese Chemical Letters, 2024, 35(6): 109680-. doi: 10.1016/j.cclet.2024.109680
15. [15]
  Wenhao Wang , Siyuan Peng , Zhengwei Huang , Xin Pan . Tuning amino/hydroxyl ratios of nanovesicles to manipulate protein corona-mediated in vivo fate. Chinese Chemical Letters, 2024, 35(11): 110134-. doi: 10.1016/j.cclet.2024.110134
16. [16]
  Yuanzheng Wang , Chen Zhang , Shuyan Han , Xiaoli Kong , Changyun Quan , Jun Wu , Wei Zhang . Cancer cell membrane camouflaged biomimetic gelatin-based nanogel for tumor inhibition. Chinese Chemical Letters, 2024, 35(11): 109578-. doi: 10.1016/j.cclet.2024.109578
17. [17]
  Xiangqian Cao , Chenkai Yang , Xiaodong Zhu , Mengxin Zhao , Yilin Yan , Zhengnan Huang , Jinming Cai , Jingming Zhuang , Shengzhou Li , Wei Li , Bing Shen . Synergistic enhancement of chemotherapy for bladder cancer by photothermal dual-sensitive nanosystem with gold nanoparticles and PNIPAM. Chinese Chemical Letters, 2024, 35(8): 109199-. doi: 10.1016/j.cclet.2023.109199
18. [18]
  Lin Li , Bingjun Sun , Jin Sun , Lin Chen , Zhonggui He . Binary prodrug nanoassemblies combining chemotherapy and ferroptosis activation for efficient triple-negative breast cancer therapy. Chinese Chemical Letters, 2024, 35(10): 109538-. doi: 10.1016/j.cclet.2024.109538
19. [19]
  Jia-Qi Feng , Xiang Tian , Rui-Ge Cao , Yong-Xiu Li , Wen-Long Liu , Rong Huang , Si-Yong Qin , Ai-Qing Zhang , Yin-Jia Cheng . An AIE-based theranostic nanoplatform for enhanced colorectal cancer therapy: Real-time tumor-tracking and chemical-enhanced photodynamic therapy. Chinese Chemical Letters, 2024, 35(12): 109657-. doi: 10.1016/j.cclet.2024.109657
20. [20]
  Tingting Hu , Chao Shen , Xueyan Wang , Fengbo Wu , Zhiyao He . Tumor microenvironment-sensitive polymeric nanoparticles for synergetic chemo-photo therapy. Chinese Chemical Letters, 2024, 35(11): 109562-. doi: 10.1016/j.cclet.2024.109562

Get Citation

PDF

XML

Metrics

PDF Downloads(0)
Abstract views(156)
HTML views(3)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142